布鲁顿的氨酸激酶作为多发性硬化症的有前途的治疗点
Darius Saberi1,2, Anastasia Geladaris2,3, Sarah Dybowski3
1Department of Neurology, University Medical Center, Göttingen, Germany.
Expert opinion on therapeutic targets
|June 5, 2023
概括
布鲁顿的氨酸激酶 (BTK) 抑制显示了通过向中枢神经系统炎症来治疗渐进性多发性硬化症 (MS) 的前景. 这种方法可能会提供一种新的策略,在当前治疗方法不足的情况下阻止疾病的进展.
科学领域:
- 神经免疫学 神经免疫学
- 中枢神经系统 (CNS) 疾病
- 脱线性疾病 脱线性疾病
背景情况:
- 多发性硬化症 (MS) 是中枢神经系统脱髓化的主要原因.
- 目前的多发性硬化症治疗有效地治疗复发,但不能阻止疾病的进展.
- 由微质驱动的中枢神经系统分隔的炎症是渐进性MS的关键.
研究的目的:
- 探索布鲁顿氨酸激酶 (BTK) 抑制作为渐进性MS的治疗策略.
- 讨论驱动MS进展的因素以及BTK抑制如何抵消这些因素.
- 总结关于BTK抑制抑制MS进展的临床数据.
主要方法:
- 对MS病理生理学现有文献的综述.
- 分析BTK在免疫细胞 (B细胞,微质细胞,巨细胞) 激活中的作用.
- 对MS治疗中BTK抑制剂的临床数据的评估.
主要成果:
- BTK在激活参与中枢神经系统炎症的免疫细胞方面发挥着至关重要的作用.
- 抑制BTK是一种潜在的治疗途径,可以治疗渐进的MS.
- 临床数据表明,BTK抑制剂可能有助于阻止多发性硬化症的进展.
结论:
- 比特基基抑制是渐进性多发性硬化症治疗的有希望的治疗标.
- 了解中枢神经系统内在机制对于开发新的MS治疗方法至关重要.
- 针对BTK可能会提供一种新的方法来管理慢性渐进性MS.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Enzyme-linked Receptors
78.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.9K
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Receptor Tyrosine Kinases
13.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.2K
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K


